Elacestrant, a selective estrogen receptor degrader, demonstrated significant improvements in progression-free survival (PFS) ...

Immunotherapy is the brightest new weapon in fight against cancer. Thank Dr. Steven Rosenberg, who 40 years ago successfully ...

A month has gone by since the last earnings report for Exelixis (EXEL). Shares have added about 10.8% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up ...

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne ...

Learn about the key tests and methods used to diagnose stomach cancer, including endoscopy, biopsy, imaging studies, and more ...

As we observe Stomach Cancer Awareness Month, it's important to educate ourselves on the risk factors, symptoms, and most common metastasis sites for this deadly disease. With early detection and ...

HOUSTON -- Two-thirds of patients with PI3K -mutant brain metastases responded to the maximum tolerated dose (MTD) of the ...

The combination of chemotherapy and radioembolization appeared safe and effective in patients with well-differentiated, liver-dominant, grade 3 NETs.

Receives FDA agreement to initiate the ReSPECT-LM Phase 1 multiple administration dose escalation trial of Rhenium (186Re) Obisbemeda for LM ...

Split designed to achieve compliance with Nasdaq minimum bid price requirementsBOSTON, Nov. 25, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: RNAZ) (“TransCode” or the “Company”), the RNA Oncology Company™ ...